Circulating tumor cells in sarcomas: a brief review
详细信息 查看全文
- 作者：Le Chang (1)
Greg Asatrian (1)
Sarah M. Dry (1)
Aaron W. James (1) - 关键词：Circulating tumor cell ; Sarcoma detection ; Ewing’s sarcoma ; RT ; PCR ; Translocation sarcoma
- 刊名：Medical Oncology
- 出版年：2015
- 出版时间：January 2015
- 年：2015
- 卷：32
- 期：1
- 全文大小：196 KB
- 参考文献：1. National Institute of Cancer. A snapshot of sarcoma. 2013. http://www.cancer.gov/researchandfunding/snapshots/pdf/Sarcoma-Snapshot.pdf. Accessed 20 Nov 2014.
2. Leung CT, Brugge JS. Tumor self-seeding: bidirectional flow of tumor cells. Cell. 2009;139(7):1226-. CrossRef
3. Sieuwerts AM, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009;101(1):61-. CrossRef
4. Allard WJ, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10(20):6897-04. CrossRef
5. Hou JM, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol. 2009;175(2):808-6. CrossRef
6. Hayes DF, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12(14 Pt 1):4218-4. CrossRef
7. Cristofanilli M, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005;23(7):1420-0. CrossRef
8. de Bono JS, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302-. CrossRef
9. Cohen SJ, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20(7):1223-. CrossRef
10. Satelli A, et al. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 2014;74(6):1645-0. CrossRef
11. Wong IH, Chan AT, Johnson PJ. Quantitative analysis of circulating tumor cells in peripheral blood of osteosarcoma patients using osteoblast-specific messenger RNA markers: a pilot study. Clin Cancer Res. 2000;6(6):2183-.
12. Burchill SA, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1?year. J Clin Oncol. 2001;19(6):1795-01.
13. Hofman VJ, et al. Cytopathologic detection of circulating tumor cells using the isolation by size of epithelial tumor cell method: promises and pitfalls. Am J Clin Pathol. 2011;135(1):146-6. CrossRef
14. Avigad S, et al. The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer. 2004;100(5):1053-. CrossRef
15. Schleiermacher G, et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol. 2003;21(1):85-1. CrossRef
16. Peter M, et al. Sensitive detection of occult Ewing’s cells by the reverse transcriptase-polymerase chain reaction. Br J Cancer. 1995;72(1):96-00. CrossRef
17. Fagnou C, et al. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing’s tumor. Société Fran?aise d’Oncologie Pédiatrique. J Clin Oncol. 1998;16(5):1707-1.
18. Zoubek A, et al. Predictive potential - 作者单位：Le Chang (1)
Greg Asatrian (1)
Sarah M. Dry (1)
Aaron W. James (1)
1. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, 10833 Le Conte Ave., 13-145 CHS, Los Angeles, CA, 90095, USA - ISSN：1559-131X
文摘
Although rare, sarcomas represent a source of significant morbidity and mortality with nearly one reported death for every two new diagnoses. The detection and surveillance of circulating tumor cells (or CTCs) has been found to have significant clinical utility in epithelial malignancies, such as carcinoma of the colon, breast and prostate. Here, we summarize what is known regarding CTCs in sarcomas. Although still in its relative infancy, the detection of CTCs in sarcoma patients may help to diagnose and predict recurrence or metastasis as well as improve the overall management of sarcoma patients. CTCs are most often detected via reverse transcriptase polymerase chain reaction or antibody-based detection of cell surface proteins, including flow cytometry. Samples may be obtained from either peripheral blood or bone marrow. CTC detection in translocation sarcomas is perhaps most promising, as a recurrent abnormal gene fusion product can be detected in involved individuals but not in the normal patient. Studies in Ewing’s sarcoma/peripheral neuroectodermal tumor, synovial sarcoma and alveolar soft part sarcoma have confirmed the feasibility of this approach. Other investigators have turned toward detection of more universal markers of sarcomas, such as the pan-mesenchymal marker Vimentin. In the case of osteosarcoma, more specific markers of osteogenic differentiation (Type I Collagen) have been utilized. In summary, although in its relative nascency, the use of CTC detection for the management of sarcoma patients shows initial promise.